{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T11:27:31Z","timestamp":1765625251035,"version":"3.48.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.pnpbp.2025.111554","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T17:22:29Z","timestamp":1762190549000},"page":"111554","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Distinct functional profiles of partial agonist antipsychotics in cAMP and \u03b2-arrestin signaling mechanisms of dopamine D2 and D3 receptors in vitro"],"prefix":"10.1016","volume":"143","author":[{"given":"Katalin","family":"Dom\u00e1ny-Kov\u00e1cs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e1ndor","family":"Kolok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalma","family":"Kurk\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zs\u00f3fia","family":"Bekes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferenc","family":"Horti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amrita","family":"Bobok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f3zsef","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zolt\u00e1n","family":"Kapui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bal\u00e1zs","family":"Lendvai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e1s","family":"Visegr\u00e1dy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9la","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"45","key":"10.1016\/j.pnpbp.2025.111554_bb0005","doi-asserted-by":"crossref","first-page":"18488","DOI":"10.1073\/pnas.1104807108","article-title":"Discovery of \u03b2-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy","volume":"108","author":"Allen","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.pnpbp.2025.111554_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/bph.12906","article-title":"Dopamine receptors. IUPHAR review 13","volume":"172","author":"Beaulieu","year":"2015","journal-title":"Br. J. Pharmacol."},{"issue":"23","key":"10.1016\/j.pnpbp.2025.111554_bb0025","doi-asserted-by":"crossref","first-page":"10601","DOI":"10.1021\/acs.jmedchem.6b01208","article-title":"Discovery of G protein-biased D2 dopamine receptor partial agonists","volume":"59","author":"Chen","year":"2016","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111554_bb0030","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41593-021-00971-w","article-title":"Structure based design of novel third-generation antipsychotic drug lead with potential antidepressant potential","volume":"25","author":"Chen","year":"2022","journal-title":"Nat. Neurosci."},{"issue":"11","key":"10.1016\/j.pnpbp.2025.111554_bb0040","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/ijcp.12752","article-title":"The ABC\u2019s of dopamine receptor partial agonists aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out","volume":"69","author":"Citrome","year":"2015","journal-title":"Int. J. Clin. Pract."},{"issue":"24","key":"10.1016\/j.pnpbp.2025.111554_bb0045","doi-asserted-by":"crossref","first-page":"5846","DOI":"10.1523\/JNEUROSCI.0310-17.2017","article-title":"D3 receptors regulate excitability in a unique class of prefrontal pyramidal cells","volume":"37","author":"Clarkson","year":"2017","journal-title":"J. Neurosci."},{"issue":"3","key":"10.1016\/j.pnpbp.2025.111554_bb0050","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0165-6147(93)90070-Z","article-title":"The Cheng-Prusoff relationship: something lost in the translation","volume":"14","author":"Craig","year":"1993","journal-title":"Trends Pharmacol. Sci."},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111554_bib296","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1177\/0269881108089586","article-title":"Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour","volume":"23","author":"Dahan","year":"2009","journal-title":"J. Psychopharmacol."},{"issue":"Art 58","key":"10.1016\/j.pnpbp.2025.111554_bb0055","article-title":"Role of Beta-Arrestin downstream of dopamine receptors in the basal ganglia","volume":"5","author":"Del\u2019Guidice","year":"2011","journal-title":"Front. Neuroanat."},{"key":"10.1016\/j.pnpbp.2025.111554_bb0060","series-title":"Small Molecule Therapeutics for Schizophrenia. Topics in Medicinal Chemistry. (Vol. 13)","article-title":"Antipsychotics and the dopamine serotonin connection. Top Med Chem 13: 1-50","author":"Ellenbroek","year":"2015"},{"key":"10.1016\/j.pnpbp.2025.111554_bb0065","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/fcp.12812","article-title":"Receptor density influences the recruitment bias of aripiprazole and brexpiprazole at the dopamine D2L receptor","volume":"36","author":"Ferraiolo","year":"2022","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.pnpbp.2025.111554_bb0070","doi-asserted-by":"crossref","first-page":"6103","DOI":"10.3390\/ijms21176103","article-title":"A split luciferase complementation assay for the quantification of \u03b2-arrestin2 recruitment to dopamine D2-like receptors","volume":"21","author":"Forster","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.pnpbp.2025.111554_bb0075","doi-asserted-by":"crossref","first-page":"12509","DOI":"10.1038\/s41598-018-30794-y","article-title":"Binding kinetics of cariprazine and aripiprazole at the dopamine D3 receptor","volume":"8","author":"Frank","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.pnpbp.2025.111554_bb0080","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1038\/s41380-024-02531-7","article-title":"Pharmacological fingerprint of antipsychotic drugs at the serotonin 5-HT2A receptor","volume":"29","author":"Gaitonde","year":"2024","journal-title":"Mol. Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111554_bb0085","first-page":"73","article-title":"Cariprazine exerts antimanic properties and interferes with dopamine D2 receptor \u00df-arrestin interaction","volume":"3","author":"Gao","year":"2014","journal-title":"Pharmacol Res Prespect"},{"key":"10.1016\/j.pnpbp.2025.111554_bb0090","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1007\/s00213-016-4382-y","article-title":"Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3\/D2 receptor ligand [11C]-(+)-PHNO","volume":"233","author":"Girgis","year":"2016","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2025.111554_bb0095","first-page":"S595","article-title":"In vivo dopamine D3 and D2 receptor occupancy profile of cariprazine versus aripiprazole: A PET study","volume":"42","author":"Girgis","year":"2017","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.pnpbp.2025.111554_bb0100","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/s41386-019-0590-6","article-title":"A positron emission tomography occupancy study of brexpiprazole at dopamine D2 and D3 and serotonin 5-HT1A and 5-HT2A receptors, and serotonin reuptake transporters in subjects with schizophrenia","volume":"45","author":"Girgis","year":"2020","journal-title":"Neuropsychopharmacol"},{"issue":"8","key":"10.1016\/j.pnpbp.2025.111554_bb0105","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1176\/appi.ajp.2008.07101574","article-title":"Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]Fallypride PET study","volume":"165","author":"Gr\u00fcnder","year":"2008","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111554_bb0115","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0014-2999(80)90220-4","article-title":"Phenoxybenzamine discriminates multiple dopamine receptors","volume":"65","author":"Hamblin","year":"1980","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pnpbp.2025.111554_bb0120","article-title":"Molecular imaging of dopamine partial agonists in humans: implications for clinical practice","volume":"13","author":"Hart","year":"2022","journal-title":"Front. Psychol."},{"key":"10.1016\/j.pnpbp.2025.111554_bb0125","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1124\/mol.118.113290","article-title":"Involvement of 5-HT1A and 5-HT2A receptors but not \u03b12-adrenoceptors in the acute electrophysiological effects of cariprazine in the rat brain in vivo","volume":"94","author":"Herman","year":"2018","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.pnpbp.2025.111554_bb0130","series-title":"2019 Wiley-VCH Verlag GmbH","first-page":"83","article-title":"Dopamine partial Agonists \u2013 Discovery, evolution and therapeutic potential. In Successful Drug Discovery, First Edition","author":"Jacobson","year":"2019"},{"key":"10.1016\/j.pnpbp.2025.111554_bb0135","doi-asserted-by":"crossref","first-page":"art 107704","DOI":"10.1016\/j.neuropharm.2019.107704","article-title":"Antipsychotics: mechanisms underlying clinical response and side effects and novel treatment approaches based on pathophysiology","volume":"172","author":"Kaar","year":"2020","journal-title":"Neuropharmacol"},{"issue":"7","key":"10.1016\/j.pnpbp.2025.111554_bb0140","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.pnpbp.2003.09.004","article-title":"Half century of antipsychotics and still a central role for dopamine D2 receptors","volume":"27","author":"Kapur","year":"2003","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111554_bb0145","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1124\/jpet.110.173948","article-title":"Functional selectivity and biased receptor signaling","volume":"336","author":"Kenakin","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111554_bb0150","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1124\/jpet.109.160432","article-title":"Cariprazine (RGH-188), a dopamine D3 receptor-preferring, D3\/D2 dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile","volume":"333","author":"Kiss","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pnpbp.2025.111554_bb0160","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.785592","article-title":"Potential mechanisms for why not all antipsychotics are able to occupy dopamine D3 receptors in the brain in vivo","volume":"13","author":"Kiss","year":"2022","journal-title":"Front Psychiatry"},{"issue":"8","key":"10.1016\/j.pnpbp.2025.111554_bb0165","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.neuropharm.2008.03.015","article-title":"Recruitment of \u03b2-arrestin2 to dopamine D2 receptor: insights into anti-psychotic and anti-parkinsonian drug receptor signaling","volume":"54","author":"Klewe","year":"2008","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111554_bb0170","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.pnpbp.2011.08.007","article-title":"Increasing the density of the D2L receptor and manipulating the receptor environment are required to evidence the partial agonist properties of aripiprazole","volume":"36","author":"Koener","year":"2012","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.pnpbp.2025.111554_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ijnp\/pyu046","article-title":"Agonist and antagonist effects of aripiprazole on D2-like receptors controlling rat brain dopamine synthesis depend on the the dopaminergic tone","volume":"18","author":"Ma","year":"2015","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.pnpbp.2025.111554_bb0185","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1124\/jpet.114.213793","article-title":"Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator","volume":"350","author":"Maeda","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"5","key":"10.1016\/j.pnpbp.2025.111554_bb0190","doi-asserted-by":"crossref","first-page":"488","DOI":"10.2174\/138161210790361461","article-title":"Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?","volume":"16","author":"Mailman","year":"2010","journal-title":"Curr. Pharm. Des."},{"issue":"9","key":"10.1016\/j.pnpbp.2025.111554_bb0195","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1176\/appi.ajp.2007.06091479","article-title":"Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study","volume":"64","author":"Mamo","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2025.111554_bb0200","doi-asserted-by":"crossref","first-page":"13656","DOI":"10.1073\/pnas.0803522105","article-title":"Antagonism of dopamine D2 receptor\/beta-arrestin2 interaction is a common property of clinically effective antipsychotics","volume":"105","author":"Masri","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.pnpbp.2025.111554_bb0205","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.781946","article-title":"Dopamine receptor partial agonists: do they differ in their clinical efficacy","volume":"12","author":"Mohr","year":"2022","journal-title":"Front Psychiatry"},{"issue":"1074","key":"10.1016\/j.pnpbp.2025.111554_bib297","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S0140-6736(17)30060-0","article-title":"Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial","volume":"389","author":"N\u00e9meth","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111554_bb0215","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1755-5949.2010.00222.x","article-title":"Antipsychotic occupancy of dopamine receptors in schizophrenia","volume":"17","author":"Nord","year":"2011","journal-title":"CNS Neurosci. Ther."},{"issue":"585\u2013595","key":"10.1016\/j.pnpbp.2025.111554_bb0220","first-page":"2014","article-title":"Acute effects of brexpiprazole on serotonin, dopamine, and norepinephrine systems: an in vivo electrophysiologic characterization","volume":"351","author":"Oosterhof","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.pnpbp.2025.111554_bb0225","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1124\/mol.52.3.508","article-title":"Selective inhibition of adenylyl cyclase type V by the dopamine D3 receptor","volume":"52","author":"Robinson","year":"1997","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.pnpbp.2025.111554_bb0230","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.biopsych.2023.03.006","article-title":"Arrestin-3 agonism at dopamine D3 receptors defines a subclass of second-generation antipsychotics that promotes drug tolerance","volume":"94","author":"Schamiloglu","year":"2023","journal-title":"Biol. Psychiatry"},{"issue":"9","key":"10.1016\/j.pnpbp.2025.111554_bb0235","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.euroneuro.2013.06.005","article-title":"Schizophrenia and dopamine receptors","volume":"23","author":"Seeman","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.pnpbp.2025.111554_bb0240","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00213-011-2343-z","article-title":"Occupancy of dopamine D2 and D3 and serotonin 5-HT1A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography","volume":"218","author":"Seneca","year":"2011","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2025.111554_bb0245","series-title":"Antipsychotic Agents. In Stahl\u2019s Essential Psychopharmacology, Neuroscientific Basis and Practical Applications","first-page":"129","author":"Stahl","year":"2013"},{"key":"10.1016\/j.pnpbp.2025.111554_bb0250","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1017\/S1092852916000043","article-title":"Mechanism of action of cariprazine","volume":"21","author":"Stahl","year":"2016","journal-title":"CNS Spectr."},{"issue":"1\u20133","key":"10.1016\/j.pnpbp.2025.111554_bb0255","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejphar.2008.09.008","article-title":"Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors","volume":"597","author":"Tadori","year":"2008","journal-title":"Eur. J. Pharmacol."},{"issue":"1\u20133","key":"10.1016\/j.pnpbp.2025.111554_bb0260","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ejphar.2009.02.007","article-title":"Receptor reserve-dependent properties of antipsychotics at human dopamine receptors","volume":"607","author":"Tadori","year":"2009","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.pnpbp.2025.111554_bb0265","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ejphar.2011.07.020","article-title":"In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors","volume":"668","author":"Tadori","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pnpbp.2025.111554_bib298","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejphar.2005.02.051","article-title":"Aripiprazole\u2019s low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic","volume":"515","author":"Tadori","year":"2005","journal-title":"Eur J Pharmacol"},{"issue":"50","key":"10.1016\/j.pnpbp.2025.111554_bb0270","doi-asserted-by":"crossref","first-page":"E8178","DOI":"10.1073\/pnas.1614347113","article-title":"Distinct cortical and striatal actions of a \u03b2-arrestin\u2013biased dopamine D2 receptor ligand reveal unique antipsychotic-like properties","volume":"113","author":"Urs","year":"2016","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111554_bb0275","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1021\/acs.jproteome.2c00707","article-title":"Phosphoproteomic analysis of dopamine D2 receptor signaling reveals interplay of G protein- and \u03b2-arrestin-mediated effects","volume":"22","author":"Wenk","year":"2022","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.pnpbp.2025.111554_bb0280","doi-asserted-by":"crossref","first-page":"17239","DOI":"10.1021\/acs.jmedchem.1c01327","article-title":"2-Phenylcyclopropylmethylamine derivatives as dopamine D2 receptor partial agonists: design, synthesis, and biological evaluation","volume":"64","author":"Yan","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pnpbp.2025.111554_bb0285","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/j.celrep.2016.06.098","article-title":"\u03b2-Arrestin-dependent dopaminergic regulation of calcium channel activity in the axon initial segment","volume":"16","author":"Yang","year":"2016","journal-title":"Cell Rep."},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111554_bb0290","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0893-133X(02)00304-4","article-title":"Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14579): a study using positron emission tomography and [11C]-raclopride","volume":"27","author":"Yokoi","year":"2002","journal-title":"Neuropsychopharmacol"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584625003082?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584625003082?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T11:25:23Z","timestamp":1765625123000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584625003082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":54,"alternative-id":["S0278584625003082"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2025.111554","relation":{},"ISSN":["0278-5846"],"issn-type":[{"type":"print","value":"0278-5846"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Distinct functional profiles of partial agonist antipsychotics in cAMP and \u03b2-arrestin signaling mechanisms of dopamine D2 and D3 receptors in vitro","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2025.111554","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"111554"}}